Navigating the preclinical “Valley of Death”: Scaling from Discovery to Tox Batch

Client Context

A virtual biotechnology company with a pipeline of novel oncology targets had successfully identified a promising lead candidate from its internal Lead Optimisation (LO) programme. The compound, a highly selective small molecule, demonstrated excellent in vitro efficacy and a favourable early ADME profile, making it a priority for preclinical development.

The Challenge: Navigating the “Valley of Death”

The transition from a successful Lead Optimisation campaign (operating at the milligram scale) to the necessary gram-to-kilogram required for Non-GLP, and subsequent GLP toxicology studies, is often referred to as the “Valley of Death” in drug discovery.

The client faced two critical challenges:

1. Scale-Up Incompatibility: The synthetic route developed by the Discovery Chemistry team was efficient at the sub-gram scale but relied on reagents and chromatography steps that were prohibitively expensive, time-consuming, or unsafe to scale to the multi-gram level.
2. Timeline Pressure: With the lead candidate showing exceptional promise, the internal deadline for initiating Non-GLP toxicology studies was aggressive. Any delay in delivering the required 50 grams of high-purity material would jeopardise the project timeline and increase overall development risk.

The client recognised that outsourcing this specialised, transitional phase to a partner who understood both Discovery and early Process Chemistry was essential to maintain momentum.

Apex Molecular’s Solution

Apex Molecular were engaged based on our unique specialisation as a CRO focused on the entire preclinical journey, from early-stage discovery chemistry (Hit-to-Lead) through to delivering the Non-GLP toxicology batch. Our approach was not just to scale the synthesis, but to perform early-stage process optimisation in parallel with the final stages of Lead Optimisation.

Key components of the Apex Molecular strategy:

• Route Assessment and Scouting (LO to Process Transition): We immediately assessed the existing milligram route and identified bottlenecks (high-cost reagents, low-mass-throughput purifications).
  Within four weeks, our chemists successfully executed a route-scouting programme, developing two viable, synthetic routes that utilised cheaper, commercially available bulk reagents and chromatography-free purification steps.
• Impurity Profiling and Control: A critical requirement for a Tox batch is known purity and impurity profiles. Our analytical team worked in unison with the synthetic chemists to identify, synthesise, and quantify potential route-specific impurities. This early control ensured the final batch met the strict quality and regulatory standards required for toxicology submission.
• Gram-to-Kilogram Delivery: The final, optimised route was executed at our dedicated scale-up lab. By maintaining a lean, iterative process chemistry mindset, we were able to seamlessly transition from producing single grams for final in vivo testing to executing the full Non-GLP batch.

The Results

By leveraging Apex Molecular’s specialist expertise in bridging the gap between Lead Optimisation and preclinical development, the client achieved a major milestone ahead of their internal target.

Apex Molecular successfully delivered the required 50 grams of high-purity compound six weeks ahead of the client’s internal projections, enabling the timely initiation of the Non-GLP toxicology studies. This allowed the client’s internal drug developers to focus solely on mechanism of action and biological evaluation, while we efficiently managed the critical chemical manufacturing requirements. The successful execution demonstrated the value of a specialised CRO partnership in minimising attrition and risk during the precarious transition across the preclinical “Valley of Death.”

Apex Molecular specialises in preclinical drug discovery, from early-stage discovery chemistry and Hit-to-Lead programmes, through Lead Optimisation, and scale-up for Non-GLP toxicology batches.